Intersect ENT shares not pricing in ‘number of tailwinds,’ says Piper Jaffray

After attending the American Academy of Otolaryngology-Head and Neck Surgery conference in Atlanta, Piper Jaffray analyst Matt O’Brien continues to recommend purchase of Intersect ENT. The analyst says his meetings at the conference, including one with CFO Jeri Hilleman, were upbeat and gave him further conviction that there are a “number of tailwinds ahead of the company not yet to be baked into the stock.” The clinician panel provided for bullish commentary on Contour, and only 50% of Propel accounts use it, so there is a “long runway,” O’Brien tells investors in a research note. He keeps an Overweight rating on Intersect ENT with a $40 price target.
https://thefly.com/landingPageNews.php?id=2801301